Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
Status:
Terminated
Trial end date:
2019-08-16
Target enrollment:
Participant gender:
Summary
Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor
activity in the patients with GC. The purpose of this study is to determine whether apatinib
plus chemotherapy drug can improve progression free survival compared with chemotherapy drug
in patients with metastatic the non-small cell lung cancer who failed one lines of
chemotherapy.